| Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies A Necchi, D Raggi, A Gallina, R Madison, M Colecchia, R Luciano, ... European urology 77 (4), 439-446, 2020 | 275 | 2020 |
| Impact of molecular subtyping and immune infiltration on pathological response and outcome following neoadjuvant pembrolizumab in muscle-invasive bladder cancer A Necchi, D Raggi, A Gallina, JS Ross, E Farè, P Giannatempo, ... European urology 77 (6), 701-710, 2020 | 146 | 2020 |
| Risks from deferring treatment for genitourinary cancers: a collaborative review to aid triage and management during the COVID-19 pandemic CJD Wallis, G Novara, L Marandino, A Bex, AM Kamat, RJ Karnes, ... European urology 78 (1), 29-42, 2020 | 145 | 2020 |
| Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy E Ghisoni, A Wicky, H Bouchaab, M Imbimbo, J Delyon, BG Moura, ... European journal of cancer 149, 153-164, 2021 | 122 | 2021 |
| Multiparametric magnetic resonance imaging as a noninvasive assessment of tumor response to neoadjuvant pembrolizumab in muscle-invasive bladder cancer: preliminary findings … A Necchi, M Bandini, G Calareso, D Raggi, F Pederzoli, E Farè, ... European urology 77 (5), 636-643, 2020 | 92 | 2020 |
| Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016 L Marandino, A La Salvia, C Sonetto, E De Luca, D Pignataro, C Zichi, ... Annals of oncology 29 (12), 2288-2295, 2018 | 87 | 2018 |
| Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study☆ M Bandini, EA Gibb, A Gallina, D Raggi, L Marandino, M Bianchi, JS Ross, ... Annals of Oncology 31 (12), 1755-1763, 2020 | 76 | 2020 |
| Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial G Basile, M Bandini, EA Gibb, JS Ross, D Raggi, L Marandino, ... Clinical Cancer Research 28 (23), 5107-5114, 2022 | 45 | 2022 |
| Predicting the pathologic complete response after neoadjuvant pembrolizumab in muscle-invasive bladder cancer M Bandini, JS Ross, D Raggi, A Gallina, M Colecchia, R Lucianò, ... JNCI: Journal of the National Cancer Institute 113 (1), 48-53, 2021 | 45 | 2021 |
| COVID-19 emergency and the need to speed up the adoption of electronic patient-reported outcomes in cancer clinical practice L Marandino, A Necchi, M Aglietta, M Di Maio JCO oncology practice 16 (6), 295, 2020 | 44 | 2020 |
| Association between human papillomavirus infection and outcome of perioperative nodal radiotherapy for penile carcinoma M Bandini, JS Ross, Y Zhu, DW Ye, AA Ornellas, N Watkin, BA Ayres, ... European Urology Oncology 4 (5), 802-810, 2021 | 40 | 2021 |
| Targetable gene fusions and aberrations in genitourinary oncology F Pederzoli, M Bandini, L Marandino, SM Ali, R Madison, J Chung, ... Nature Reviews Urology 17 (11), 613-625, 2020 | 40 | 2020 |
| Quality of life analysis in lung cancer: a systematic review of phase III trials published between 2012 and 2018 ML Reale, E De Luca, P Lombardi, L Marandino, C Zichi, D Pignataro, ... Lung Cancer 139, 47-54, 2020 | 40 | 2020 |
| Is there a detrimental effect of antibiotic therapy in patients with muscle-invasive bladder cancer treated with neoadjuvant pembrolizumab? F Pederzoli, M Bandini, D Raggi, L Marandino, G Basile, M Alfano, ... European urology 80 (3), 319-322, 2021 | 38 | 2021 |
| Immune checkpoint inhibitors in advanced prostate cancer: current data and future perspectives SE Rebuzzi, P Rescigno, F Catalano, V Mollica, UM Vogl, L Marandino, ... Cancers 14 (5), 1245, 2022 | 30 | 2022 |
| Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: interim results of the open-label, single-arm … P Giannatempo, D Raggi, L Marandino, M Bandini, E Fare, G Calareso, ... Annals of Oncology 31 (12), 1764-1772, 2020 | 30 | 2020 |
| Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer AG Robertson, K Meghani, LF Cooley, KA McLaughlin, LA Fall, Y Yu, ... Nature communications 14 (1), 2126, 2023 | 28 | 2023 |
| HPV vaccination and HPV-related malignancies: impact, strategies and optimizations toward global immunization coverage G Giannone, AR Giuliano, M Bandini, L Marandino, D Raggi, W Earle, ... Cancer treatment reviews 111, 102467, 2022 | 27 | 2022 |
| Anorectal and genital mucosal melanoma: diagnostic challenges, current knowledge and therapeutic opportunities of rare melanomas M Ottaviano, EF Giunta, L Marandino, M Tortora, L Attademo, D Bosso, ... Biomedicines 10 (1), 150, 2022 | 26 | 2022 |
| Erdafitinib for the treatment of urothelial cancer L Marandino, D Raggi, P Giannatempo, E Farè, A Necchi Expert review of anticancer therapy 19 (10), 835-846, 2019 | 26 | 2019 |
